SAN DIEGO — Early study results have shown a meaningful decrease in IOP in glaucoma patients treated with OTX-TIC, an intracameral travoprost implant, according to a speaker.
OTX-TIC (Ocular Therapeutix) is a biodegradable, preservative-free implant of travoprost-loaded microparticles in hydrogel, which is administered via a single injection.
The prospective, multicenter, open-label clinical study is enrolling 10 patients in two dosing cohorts.
The first cohort of five patients, which received the lower dose, had an average IOP reduction in their implant-treated eye greater than in their
Uncategorized